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The aim of this international phase II trial was to determine the efficacy and safety profile of weekly vinorelbine plus trastuzumab as
first-line chemotherapy for women with HER 2-overexpressing metastatic breast cancer. Sixty-nine patients with tumours
overexpressing HER 2 received vinorelbine: 30mgm
 2week
 1 and trastuzumab: 4mgkg
 1 on day 1 as a loading dose followed by
2mgkg
 1week
 1 starting on day 8. Sixty-two patients were evaluable for response and 69 patients were evaluable for toxicity. The
overall response rate was 62.9%. The median time to response was 8.4 weeks, the median duration of response was 17.5 months,
the median progression-free survival was 9.9 months (95% CI, 5.6–12.1) and the one-year progression-free survival was 39.1%. The
median survival for all patients was 23.7 months (95% CI, 18.4–32.6). This regimen was safe: grade 3–4 neutropenia were observed
over 17.7% of courses in 83.8% of patients, with only two episodes of febrile neutropenia (0.1%) in two patients (2.9%). Only one
patient discontinued treatment due to grade 3 symptomatic cardiac dysfunction that resolved with therapy. Vinorelbine plus
trastuzumab is one of the most active treatment regimens for patients with HER 2-positive metastatic breast cancer and
demonstrates a very favourable safety profile allowing prolonged treatment with long-term survival. This study has been presented in
part at the following conferences: The San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 2003; The American Society
of Clinical Oncology, Orlando, FL, USA, 2005.
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Advances in understanding breast cancer biology have led to the
development of targeted anticancer treatment. HER 2/neu gene
amplification, identified in 20–30% of breast cancers, is a
prognostic marker for poor clinical outcomes (Slamon et al,
1987, 1989; Berger et al, 1988; Ravdin and Chamness, 1995).
Trastuzumab is a humanised monoclonal antibody that targets the
extracellular domain of the HER 2 receptor and inhibits the
proliferation of human tumour cells overexpressing the HER 2
protein. Trastuzumab has demonstrated antitumour activity in
metastatic breast cancer in first-line treatment, or in patients who
have tumour progression after chemotherapy (Cobleigh et al, 1999;
Vogel et al, 2002). Preclinical studies indicated synergistic or
additive interactions for trastuzumab with different chemotherapy
agents (Pegram et al, 1999, 2004). Two randomised trials
comparing trastuzumab plus chemotherapy to chemotherapy
alone demonstrated an improved outcome for patients receiving
trastuzumab plus chemotherapy (Slamon et al, 2001; Marty et al,
2005). However, trastuzumab therapy can be associated with
cardiac toxicity (Slamon et al, 2001). Retrospective analyses have
found that concomitant use with anthracyclines and advanced age
are predictive factors of trastuzumab-induced cardiac dysfunction
(Seidman et al, 2002).
Among chemotherapeutic agents used in the management of
metastatic breast cancer, vinorelbine has demonstrated the great-
est antitumour synergy with trastuzumab in preclinical models
(Pegram et al, 1999, 2004). Furthermore, the weekly administration
of both agents and the lack of overlapping toxicity between these
drugs make this combination suitable for further investigation.
Several single institution or national phase II trials have been
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sconducted with this regimen as first-line therapy or in heavily
pretreated patients with metastatic breast cancer. These studies
consistently demonstrated high efficacy with limited toxicities
(Burstein et al, 2001, 2003; Jahanzeb et al, 2002; Bayo-Calero et al,
2004; Bernardo et al, 2004).
This international, open-label, phase II study was designed to
evaluate the efficacy and safety of this combination as first-line
treatment for metastatic breast cancer.
MATERIALS AND METHODS
Eligibility criteria
Eligible patients were female 418 years, with histologically proven
metastatic breast carcinoma. Other inclusion criteria included
Karnofsky performance status (KPS) score X70%, at least one
bidimensionally measurable lesion according to the World Health
Organisation (WHO) criteria and a life expectancy 416 weeks.
Adjuvant chemotherapy containing an anthracycline was allowed
if the total cumulative dose of doxorubicin or epirubicin did not
exceed 360 and 720mgm
 2, respectively. A disease-free interval
of more than 6 months between the last dose of adjuvant
chemotherapy and documentation of relapse was needed. Patients
were required to give written informed consent before study-
specific procedures were performed and to be able to comply with
the protocol for the duration of the study. Patients were required
to have normal cardiac function with left ventricular ejection
fraction (LVEF) measured by echocardiography or multigated
acquisition scan (MUGA scan) no more than 10% below the
normal limit of the institution.
Patients were ineligible if they had local relapse only, prior
chemotherapy in the metastatic setting, previous treatment with
vinca alkaloid or trastuzumab, grade 42 peripheral neuropathy,
serious illness or medical conditions such as cardiac disease,
unstable diabetes, uncontrolled hypercalcaemia or active infection.
Patients were also excluded if they were pregnant or lactating, had
central nervous system or leptomeningeal metastases, had
participated in another clinical trial with any investigational drug
within 30 days prior to the study inclusion or had a history of
another malignancy, except cured basal cell carcinoma of the skin
or excised carcinoma in situ of the cervix.
Patients were required to have adequate bone marrow
(haemoglobin value X10gdl
 1, absolute neutrophil count
X1.5 10
9l
 1 and platelet count X100 10
9l
 1), renal (serum
creatinine p130mmoll
 1) and liver function (serum bilirubin
p1.5  upper normal limit (UNL), serum glutamic–oxalic
transaminase (SGOT) or serum glutamic–pyruvic transaminase
(SGPT) p2.5 UNL, unless liver involvement).
The HER 2 status of primary or metastatic tumours was assessed
by immunohistochemistry (IHC) and fluorescent in situ hybridisa-
tion (FISH) on formalin-fixed paraffin-embedded tissue. Because
of the possibility of discrepancy between local laboratories for the
HER 2 testing with IHC, a centralised testing was implemented
(Professor Josef Ru ¨schoff, Institute of Pathology, Kassel, Ger-
many). Immunohistochemistry was performed using the DAKO
Hercept
s Test, and FISH analysis was performed using the
PathVysion HER 2 probe kit Vysis
s. Patients with HER 2 staining
assessed 3þ by IHC were eligible for the study, while those with
IHC 2þ required confirmation by FISH.
Treatment plan
Treatment was given on a weekly basis (1 cycle¼4 weeks of
treatment). The initial trastuzumab infusion was administered
intravenously at the dose of 4mgkg
 1 over 90min on day 1. The
patient remained under medical supervision for 1h following
completion of the first infusion. Subsequent weekly trastuzumab
courses were given at 2mgkg
 1 over 30min. The postinfusion
observation period for the second infusion was shortened to
30min and was withheld over subsequent administrations
provided no adverse events occurred.
Vinorelbine was administered after trastuzumab infusion at
30mgm
 2 weekly over 6–10min. The first dose of vinorelbine was
administered 2h after the trastuzumab infusion. Patients were to
receive at least 8 weeks of treatment (two cycles).
Diphenhydramine and paracetamol premedication were op-
tional. Treatment was continued until disease progression,
unacceptable toxicity or patient’s refusal to continue.
Dose modifications
There was no dose adjustment for trastuzumab. The infusion was
stopped if the patient developed chills, fever, allergic reaction or
any grade 3–4 toxicities. Trastuzumab administration was also
withheld in the event of a decline in LVEF value either X20% of
absolute units from baseline to a value above the lower normal
limit for the centre, or X10% of absolute units to a value below the
lower normal limit for the centre. Trastuzumab therapy was
reintroduced 1 month later if there was no further decline in LVEF.
Trastuzumab was permanently interrupted if New York Heart
Association (NYHA) class III/IV cardiac function impairment
occurred.
Vinorelbine was postponed for 1 week in case of grade X3
neutropenia. Following one delay of vinorelbine, the dose of
vinorelbine was permanently decreased to 25mgm
 2week
 1 for
the remainder of study treatment. In the event of grade 42
peripheral neuropathy, vinorelbine was permanently discontinued.
In case of increased SGOT/SGPT to 5.1–20.0 UNL, or bilirubin at
1.5–3.0 UNL, vinorelbine administration was postponed for 1
week and permanently discontinued in case of three consecutive
delays or SGOT/SGPT value 420.0 UNL and/or total bilirubin
value 43 UNL. Patients who experienced grade 3 or 4 neutropenia
with or without fever were allowed to receive a granulocyte colony-
stimulating factor in the subsequent cycles at the investigator’s
discretion.
Study assessments
Screening assessments were performed at baseline in all patients
within 28 days before study treatment, including medical history,
physical examination, performance status, HER 2 testing, electro-
cardiogram, LVEF, chest X-ray, tumour measurements by
computed tomography (CT), abdominal ultrasound, bone scan
and brain CT scan. On day 1 of each 4-week cycle, physical
examination and performance status were assessed and haemato-
logical and blood chemistry measurements were carried out.
Additional radiological imaging was performed as clinically
indicated.
Complete blood cells counts were performed weekly within 2
days before vinorelbine administration. LVEF measurement was
repeated every 6 months and at any time if clinically indicated.
Objective responses were assessed every 8 weeks until progres-
sion, or less than 8 weeks if early progression was suspected. The
best overall response achieved, using the standard WHO criteria
of tumour response, was reported for each patient. A complete
response (CR) required complete disappearance of all previously
detectable disease with no appearance of new lesions, and partial
response (PR) required at least a 50% decrease of the sum of the
products of the two greatest perpendicular diameters of all
measurable lesions, with no appearance of new lesions or
progression of any lesion. Both CR and PR had to be confirmed
4 weeks later. Stable disease (SD) was defined as less than 50%
decrease or a less than 25% increase in the size of one or more
measurable lesions. Progressive disease was defined as 25% or
more increase of previously described lesions, or appearance of
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responses. Clinical benefit was defined as patients achieving CR,
PR or SD maintained for a minimum of 6 months.
Adverse events and medical history were recorded throughout
the study. The WHO criteria were used to grade the adverse events.
Statistical analysis
The one-sample multiple testing procedure for phase II clinical
trials described by Fleming was used. Based on a type I error rate
of 5% and a 95% power to reject the null hypothesis of a 20%
objective response rate (complete or partial), a sample size of 60
evaluable patients was needed.
All registered patients were included in the intent-to-treat (ITT)
analysis; patients who received at least one administration of study
treatment were analysed for safety. The objective response was the
main end point for this study. The Kaplan–Meier method was
applied on overall survival, progression-free survival, duration of
response and time to treatment failure.
RESULTS
Patients’ characteristics
Between October 2000 and June 2002, 69 patients with metastatic
breast cancer screened for HER 2 status and fulfilling the eligibility
criteria were enrolled in the study at 20 sites from 13 countries.
Seven out of 69 patients were not evaluable for response, but were
included in the ITT analysis: two patients were not assessable as a
result of premature study discontinuation (one patient withdrew
from the study after the first therapy administration due to an
adverse event, the second one died during the first cycle from
sepsis), one patient had bone metastases only which was not
assessable, another patient had no measurable disease as defined
in the protocol and three other patients were not eligible due to
relapse within 6 months from early-stage chemotherapy. There-
fore, 62 patients with measurable disease were assessable for
disease response as per protocol.
The patient’s characteristics are described in Table 1. Median
age was 53 years (range 30–74 years), more than 70% of patients
had KPS X90% and the median time between initial diagnosis and
relapse was 17.8 months. Nearly all patients (97.1%) had tumour
HER 2 status 3þ determined by IHC, while two patients required
confirmation with FISH. The majority of patients had visceral
metastasis (75.4%). Sixty-five per cent of patients had prior neo/
adjuvant chemotherapy including anthracycline in the majority of
cases.
Clinical efficacy
Independent review panel observed an objective response rate of
62.9% among the 62 evaluable patients (95% CI, 49.7–74.8),
including 14.5% of CRs. Stable disease was observed in 19.4% of
patients. The clinical benefit (CRþPRþSD X6 months) was
72.6% (95% CI, 61.5–83.7) Table 2. In the ITT population, the
objective response rate was of 58% (95% CI, 45.5–69.8).
Patients who had received prior adjuvant chemotherapy with
anthracyclines or anthracyclines and taxanes had similar objective
response rates (61.9 and 54.5%, respectively), as well as those with
or without visceral involvement (63.8 and 60% of objective
response rates, respectively) Table 2. Patients anticipated to have
a worse prognosis, with a disease-free interval of less than 12
months, had an overall objective response rate of 71.4%. The
median follow-up of patients was 36.2 months. The median time to
response was 8.4 weeks (7.1–31.3 weeks) and the median duration
of response was 17.5 months (95% CI, 12.1–23.0). The time to
treatment failure was 6 months (95% CI, 5.3–8.6), the progression-
free survival was 9.9 months (95% CI, 5.6–12.1) and the median
overall survival for all patients was 23.7 months (95% CI, 18.4–
32.6) (Table 3; Figures 1 and 2).
Twenty-six patients received further radiotherapy, 24 patients
received hormonotherapy and 39 patients received further
chemotherapy.
Table 1 Patient’s characteristics
Characteristic N (%)
Included 69
Age (years)
Median 53
Range 30–74
KPS X70% 69 100
HER 2 testing
IHC 3+ 67 97.1
IHC 2+/FISH+ 2 2.9
Prior hormonotherapy 34 49.3
Prior chemotherapy 45 65.2
Neoadjuvant 5 7.2
Adjuvant 30 43.5
Both 10 14.5
Chemotherapy regimen
Anthracycline based 23 51.1
Anthracycline+taxane 13 28.9
CMF 9 20.0
Metastatic sites X2 22 31.9
Lymph nodes 35 50.7
Visceral (lung/liver) 52 75.4
Liver 38 55.1
Lung 20 29.0
Bone 31 44.9
Disease-free interval from diagnosis to first relapse (months)
Median 17.8
Range 0–202.7
CMF¼cyclophosphamide methotrexate 5-fluorouracil; FISH¼fluorescent in situ
hybridisation; IHC¼immunohistochemistry; KPS¼Karnofsky performance status.
Table 2 Antitumour efficacy
Best overall response (Independent Review Panel) N (%)
Evaluable patients 62
CR 9 14.5
PR 30 48.4
Objective response (CR+PR) (95% CI) 39 62.9 (49.7–74.8)
SD 12 19.4
Clinical benefit (CR+PR+SD X6 months) (95% CI) 45 72.6 (61.5–83.7)
PD 11 17.7
Prognostic factors of response rate (patients)
Prior chemotherapy regimen
No prior adjuvant/neoadjuvant (23) 16 69.6
Anthracycline based (21) 13 61.9
Anthracycline+taxane (11) 6 54.5
Visceral involvement (liver/lung)
Yes (47) 30 63.8
No (15) 9 60.0
Stage IV at diagnosis (12) 9 75.0
CI¼confidence interval; CR¼complete response; PD¼progressive disease;
PR¼partial response; SD¼stable disease.
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A total of 1769 administrations of vinorelbine and 2242 adminis-
trations of trastuzumab were given, with a median number of 18
(range, 1–106) and 24 (range, 1–124) administrations per patient
for vinorelbine and trastuzumab, respectively. Fourteen patients
received this regimen for more than 1 year, and four patients for
more than 2 years.
The median relative dose intensity for vinorelbine was 66.1%,
whereas that for trastuzumab was 95%. Vinorelbine treatment was
delayed more than 3 days or cancelled in 26.5% of administrations
mainly due to haematological toxicity, whereas trastuzumab
treatment was delayed more than 3 days or cancelled in 6.7% of
administrations mainly due to investigator’s decision or patient’s
convenience.
Treatment-related toxicity
The most frequent haematological toxicity (WHO grading) was
neutropenia, with grade 3–4 neutropenia observed in 83.8% of
patients over 301 (17.7%) administrations. Neutropenia was
usually brief, infrequently associated with infections and was not
cumulative (data not shown). There were only two episodes (0.1%)
of febrile neutropenia in two patients (2.9%). One of these patients
died from neutropenic sepsis. Grade 3 anaemia was reported in
only two (2.9%) patients over three (0.2%) courses. No grade 2, 3
or 4 thrombocytopenia was reported (Table 4).
Nonhaematological toxicities were mild. The most common
nonhaematological toxicity (WHO grade 3/4) attributed to study
treatment was grade 3 asthenia in six patients (8.8%) and infection
in four patients (5.9%). Other side effects were rare: grade 3
peripheral neuropathy and constipation were noticed in two
patients each (2.9%) (Table 5).
Cardiac toxicity
Eligible patients received study treatment with LVEF no more than
10% below the normal limit of the institution. The mean LVEF at
baseline was 63.8% (95% CI, 62.1–65.6), and the minimum value
during treatment remained similar at a mean of 59.1% (95% CI,
55.9–61.7) (Figure 3).
One patient experienced a decline of LVEF to 38% with
symptomatic cardiac failure 4 months after study initiation. She
was aged 68 years old with a history of hypertension. Vinorelbine
administration was postponed for 2 weeks and trastuzumab
treatment was permanently discontinued. Following initiation of
antifailure treatment, the symptoms resolved with the LVEF
normalising at 58%. Three other patients experienced asympto-
matic decline in LVEF to 41, 46 and 44%, respectively. The therapy
was interrupted for 4 weeks and only reintroduced after LVEF
increased to X50%.
DISCUSSION
Trastuzumab combined with chemotherapy is the standard of care
for women with HER 2-overexpressing metastatic breast cancer.
However, the optimal chemotherapeutic agent to combine with
trastuzumab is not established. Ideally, chemotherapy–trastuzu-
mab combinations should produce durable response rates with
minimal toxicity. In particular, the known cardiac toxicity of
trastuzumab would preclude its use with an agent also known to be
cardiotoxic. Data from preclinical models have demonstrated
synergistic interaction between trastuzumab and vinorelbine
(Pegram et al, 2004). Several phase II studies have been conducted
in the first-line setting or after progression to other chemotherapy.
This doublet has produced consistent response rates ranging from
60 to 86%, with a satisfactory tolerance profile (Burstein et al,
2001, 2003; Jahanzeb et al, 2002; Bernardo et al, 2004; Bayo-Calero
et al, 2004).
The current study evaluated the combination of vinorelbine
(30mgm
 2week
 1) and trastuzumab (4mgkg
 1 on day 1 followed
by 2mgkg
 1week
 1 starting on day 8) as first-line therapy for
HER 2-positive metastatic breast cancer patients. This is the first
international phase II trial with centralised HER 2 testing
evaluating this combination.
The short disease-free interval of 17.8 months and prior use of
adjuvant anthracyclines with or without taxane chemotherapy in
52.2% of patients underlies the aggressive nature of disease in this
Table 3 Survival data (cutoff date 1 October, 2004)
Median time to response (weeks) (range) 8.4 (7.1–31.3)
Median duration of response (months) (95% CI) 17.5 (12.1–23.0)
Median progression-free survival (months) (95% CI) 9.9 (5.6–12.1)
Median survival (months) (95% CI) 23.7 (18.4–32.6)
CI¼confidence interval.
No. of patients: 69
No. of censored data: 9
Median: 9.9
95% Cl: [5.6; 12.1]
One Year PFS: 39.1%
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Figure 1 Progression-free survival – ITT population.
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Figure 2 Overall survival – ITT population.
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median duration of response of 17.5 months compares favourably
with other trastuzumab combinations (Seidman et al, 2001; Esteva
et al, 2002; Marty et al, 2005). The duration of efficacy of the
current combination is reflected by the 39.1% disease-free survival
rate at 1 year. By 9 November 2005, two patients were still on
treatment with vinorelbine and trastuzumab after 3.5–3.6 years,
respectively.
This multicentre study confirms the efficacy of vinorelbine with
trastuzumab previously seen in other studies, with independent
radiological review avoiding investigator assessment bias. Burstein
reported 75% of response rates without grade 3–4 cardiac toxicity
in a single centre trial of weekly vinorelbine (25mgm
 2) and
trastuzumab (4mgkg
 1 on day 1 then 2mgkg
 1week
 1) used as
first- and second-line therapy (Burstein et al, 2001). In a multi-
institutional trial of the same schedule, the same author confirmed
the efficacy of trastuzumab plus vinorelbine as first-line
chemotherapy, with 68% of patients achieving an objective
response and 39% of patients remaining free of disease progres-
sion at 1 year (Burstein et al, 2003). Jahanzeb et al (2002), in a trial
of first-line vinorelbine and trastuzumab at the same schedule and
doses as the current study, reported 78% of responses among 40
patients. In addition, the time to disease progression was extended
to 17 months.
The results are in line with other reports using different
chemotherapies in combination with trastuzumab. The objective
response rate was of 50% in the study by Slamon et al (2001)
with the combination of trastuzumab and paclitaxel and 61%
in the study by Marty et al (2005) with trastuzumab plus
docetaxel.
Table 4 Worst haematological WHO grades, by evaluable patient (N¼68
a) and by evaluable administration of vinorelbine+trastuzumab (N¼1705)
Patients Administrations
Haematological toxicity Patients (overall incidence) Grade 3, N (%) Grade 4, N (%) Grade 3, N (%) Grade 4, N (%)
Anaemia 58 (85.3) 2 (2.9) — 3 (0.2) —
Leucopenia 63 (92.6) 39 (57.4) 6 (8.8) 159 (9.3) 13 (0.8)
Neutropenia 63 (92.6) 28 (41.2) 29 (42.6) 226 (13.3) 75 (4.4)
Febrile neutropenia
b 2 (2.9) — — — —
Thrombocytopenia 4 (5.9) — — — —
WHO¼World Health Organisation.
aOne patient with only one treatment administration was not evaluable for haematological toxicity.
bOne of these patients died of
neutropenic sepsis.
Table 5 Worst related nonhaematological WHO grades, by evaluable patient (N¼69) and by evaluable cycle (N¼613) of vinorelbine+trastuzumab
Patients Cycles
Nonhaematological toxicity Patients (overall incidence) Grade 3, N (%) Grade 4, N (%) Grade 3, N (%) Grade 4, N (%)
Anorexia 18 (26.1) 2 (2.9) — 3 (0.5) —
Nausea/vomiting 42 (60.9) 1 (1.4) — 1 (0.2) —
Constipation 20 (29.0) 2 (2.9) — 2 (0.3) —
Diarrhoea 18 (26.1) 1 (1.4) 1 (1.4) 1 (0.2) 1 (0.2)
Stomatitis 27 (39.1) — — — —
Peripheral neuropathy 22 (31.9) 2 (2.9) — 3 (0.5) —
Asthenia 33 (47.8) 6 (8.7) — 10 (1.6) —
Chills 15 (21.7) 1 (1.4) — 1 (0.2) —
Hair loss 25 (36.2) — — — —
Cutaneous 14 (20.3) 1 (1.4) — 1 (0.2) —
Drug fever 23 (33.3) 1 (1.4) — 1 (0.2) —
Infection 18 (26.1) 4 (5.8) — 5 (0.9) —
Local venous toxicity 16 (23.2) 1 (1.4) — 2 (0.3) —
WHO¼World Health Organisation.
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Figure 3 Mean LVEF during treatment.
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predictable and manageable. Although grade 3 or 4 neutropenia
occurred in 83.8% of patients, only two episodes (0.1%) of febrile
neutropenia occurred (2.9% of patients).
Cardiomyopathy, a serious toxicity associated with trastuzu-
mab-based therapy, has been reported in 13% of patients receiving
paclitaxel and trastuzumab (including severe events in 2% of
patients) (Slamon et al, 2001). In the study by Marty et al (2005),
one patient (1%) receiving trastuzumab and docetaxel experienced
symptomatic heart failure, and another patient experienced
symptomatic heart failure 5 months after discontinuation of
trastuzumab while receiving an investigational anthracycline for 4
months. The favourable safety profile of the vinorelbine/trastuzu-
mab combination has been observed in other trials: Burstein et al
(2003) reported only one patient with grade 3 cardiac toxicity,
whereas no grade 3–4 cardiac toxicity was seen by Jahanzeb et al
(2002).
It is important to note that cardiac toxicity was reported in 4.7%
of patients with trastuzumab monotherapy (Cobleigh et al, 1999).
The 5.9% incidence of cardiac toxicity seen in the present study
with only one patient (1.5%) experiencing symptomatic cardiac
failure is therefore similar to that seen when trastuzumab is used
alone, reflecting the absence of additional cardiac toxicity from
vinorelbine. Twenty per cent of patients were treated for more than
1 year.
In conclusion, the vinorelbine/trastuzumab regimen is an
effective and well-tolerated first-line therapy option for HER 2-
overexpressing metastatic breast cancer patients. The shorter
duration of administration without the need of a steroid
premedication and lack of cumulative side effects with marginal
cardiac toxicity provide strong argument for its choice as the
control arm in future phase III trials including trastuzumab-based
combinations.
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